Total Voting Rights and Shares as of February 28, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy DBVT?
Source: Newsfilter
- Total Shares: As of February 28, 2026, the company has a total of 278,352,082 shares, reflecting the company's stability in the market and transparency in shareholder structure, which ensures investor confidence in corporate governance.
- Total Voting Rights: The total voting rights on the same date amount to 278,352,082, indicating the distribution of voting rights at shareholder meetings, which facilitates shareholder participation in corporate decision-making processes.
- Net Voting Rights: The net voting rights stand at 278,236,200, suggesting that a certain proportion of shares lack voting rights, which may impact shareholders' influence and voice in significant decisions.
- Compliance Information: The disclosure of voting rights and share information is in accordance with Article 223-16 of the French Financial Markets Authority, enhancing market transparency and compliance, thus meeting regulatory requirements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DBVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DBVT
Wall Street analysts forecast DBVT stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.870
Low
40.00
Averages
46.40
High
51.00
Current: 21.870
Low
40.00
Averages
46.40
High
51.00
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DBV Technologies' VIASKIN Peanut Patch Achieves Phase 3 Trial Success
- Clinical Trial Success: DBV Technologies' VIASKIN peanut patch met its primary endpoint in the pivotal Phase 3 VITESSE trial, demonstrating significant desensitization in children aged 4 to 7, addressing the urgent need for safe and effective therapies.
- Efficacy Data: 46.6% of children in the treatment group were responders at 12 months compared to only 14.8% in the placebo group, indicating a significant advantage in increasing children's tolerance thresholds.
- Good Safety Profile: The therapy was generally well tolerated, with most adverse events limited to mild localized skin reactions, demonstrating its safety and acceptability in clinical applications.
- Future Plans: DBV Technologies plans to submit a Biologics License Application (BLA) to the U.S. FDA in the first half of 2026, and if approved, the VIASKIN peanut patch could become the first non-invasive, patch-based therapy for peanut allergy, presenting significant market potential.
See More
DBV Technologies to Participate in March Investor Conferences
- Investor Conference Schedule: DBV Technologies will participate in two key investor conferences in March 2026, namely the Citizens Life Sciences Conference on March 10 and the Leerink Partners Global Healthcare Conference on March 11, showcasing its latest advancements in food allergy treatments.
- Innovative Technology Introduction: The company focuses on developing its proprietary VIASKIN® patch technology, designed to introduce microgram amounts of biologically active compounds through the skin via epicutaneous immunotherapy (EPIT), aiming to re-educate the immune system and potentially transform the market.
- Clinical Trial Progress: DBV Technologies is conducting clinical trials for the VIASKIN Peanut patch targeting peanut-allergic toddlers and children aged 1 to 7, demonstrating the company's commitment to addressing significant unmet medical needs and potentially offering new treatment options for millions of allergy sufferers.
- Market Positioning and Development: Headquartered in Châtillon, France, with North American operations in Warren, NJ, DBV's ordinary shares are traded on Euronext Paris while its ADSs are listed on the Nasdaq Capital Market, reflecting its strategic positioning in the global market.
See More
Total Voting Rights and Shares as of February 28, 2026
- Total Shares: As of February 28, 2026, the company has a total of 278,352,082 shares, reflecting the company's stability in the market and transparency in shareholder structure, which ensures investor confidence in corporate governance.
- Total Voting Rights: The total voting rights on the same date amount to 278,352,082, indicating the distribution of voting rights at shareholder meetings, which facilitates shareholder participation in corporate decision-making processes.
- Net Voting Rights: The net voting rights stand at 278,236,200, suggesting that a certain proportion of shares lack voting rights, which may impact shareholders' influence and voice in significant decisions.
- Compliance Information: The disclosure of voting rights and share information is in accordance with Article 223-16 of the French Financial Markets Authority, enhancing market transparency and compliance, thus meeting regulatory requirements.
See More
DBV Technologies Presents Positive Data from VIASKIN® Peanut Patch Study
- Clinical Trial Success: At the AAAAI 2026 Annual Meeting, DBV Technologies presented data from the Phase 3 VITESSE study of the VIASKIN® Peanut Patch, showing that 83% of children increased their eliciting dose at 12 months compared to 48% in the placebo group, indicating significant efficacy of this treatment in peanut-allergic children.
- Significant Treatment Effect: Among the treated group, 46.6% of children met the treatment responder criteria at 12 months, compared to only 14.8% in the placebo group, with a difference of 31.8%, exceeding the pre-specified threshold of 15%, thus laying a solid foundation for future FDA applications.
- Good Safety Profile: The VIASKIN® Peanut Patch was well tolerated, with the majority of treatment-emergent adverse events being mild local reactions, consistent with DBV's previous Phase 3 studies, demonstrating the product's safety in clinical applications.
- Huge Market Potential: If approved, the VIASKIN® Peanut Patch would provide a non-invasive treatment option for peanut-allergic children that fits into daily activities, with DBV planning to submit a Biologics License Application to the FDA in the first half of this year, further advancing its market entry.
See More
DBV Technologies to Present VIASKIN® Data at AAAAI 2026
- Research Data Presentation: DBV Technologies will present additional data from the VITESSE Phase 3 study of the VIASKIN® Peanut Patch for children aged 4-7 at the 2026 AAAAI Annual Meeting, which is expected to enhance market awareness and trust in the product.
- Expert Panel Discussion: During the conference, a panel discussion on the potential of epicutaneous immunotherapy (EPIT) will explore the impact of early intervention in children with peanut allergies, potentially driving the adoption of new treatment options.
- Oral Abstract Presentation: DBV will deliver an oral abstract presentation on February 28, detailing the efficacy and safety of EPIT in peanut-allergic children, further validating its clinical application effectiveness.
- Exhibition Participation: DBV will exhibit at booth #1527 at the AAAAI conference, attracting attendees to learn about the latest developments in EPIT, which may facilitate the company's market share growth in food allergy treatment.
See More
DBV Technologies to Participate in Biotech Summit
- Executive Participation: DBV Technologies CEO Daniel Tassé will participate in a fireside chat at the Guggenheim Securities Biotech Summit on February 12, 2026, at 2:30 PM in New York, showcasing the company's advancements in biopharmaceuticals and likely attracting investor interest.
- Technological Innovation: DBV is focused on developing its proprietary VIASKIN® patch technology to address food allergies and other immunologic conditions, aiming to introduce microgram amounts of biologically active compounds through the skin to retrain the immune system, providing new treatment options for millions of allergy sufferers.
- Clinical Trial Progress: The company is currently conducting clinical trials of the VIASKIN® Peanut patch for peanut-allergic toddlers and children aged 1 to 7 years, demonstrating its commitment and potential to meet significant unmet medical needs in the allergy treatment space.
- Market Positioning and Growth: Headquartered in Châtillon, France, with North American operations in Warren, NJ, DBV's ordinary shares are traded on Euronext Paris while its ADSs are listed on Nasdaq, reflecting its strategic positioning in the global market.
See More
DBV Technologies' VIASKIN Peanut Patch Achieves Phase 3 Trial Success
- Clinical Trial Success: DBV Technologies' VIASKIN peanut patch met its primary endpoint in the pivotal Phase 3 VITESSE trial, demonstrating significant desensitization in children aged 4 to 7, addressing the urgent need for safe and effective therapies.
- Efficacy Data: 46.6% of children in the treatment group were responders at 12 months compared to only 14.8% in the placebo group, indicating a significant advantage in increasing children's tolerance thresholds.
- Good Safety Profile: The therapy was generally well tolerated, with most adverse events limited to mild localized skin reactions, demonstrating its safety and acceptability in clinical applications.
- Future Plans: DBV Technologies plans to submit a Biologics License Application (BLA) to the U.S. FDA in the first half of 2026, and if approved, the VIASKIN peanut patch could become the first non-invasive, patch-based therapy for peanut allergy, presenting significant market potential.
See More
DBV Technologies to Participate in March Investor Conferences
- Investor Conference Schedule: DBV Technologies will participate in two key investor conferences in March 2026, namely the Citizens Life Sciences Conference on March 10 and the Leerink Partners Global Healthcare Conference on March 11, showcasing its latest advancements in food allergy treatments.
- Innovative Technology Introduction: The company focuses on developing its proprietary VIASKIN® patch technology, designed to introduce microgram amounts of biologically active compounds through the skin via epicutaneous immunotherapy (EPIT), aiming to re-educate the immune system and potentially transform the market.
- Clinical Trial Progress: DBV Technologies is conducting clinical trials for the VIASKIN Peanut patch targeting peanut-allergic toddlers and children aged 1 to 7, demonstrating the company's commitment to addressing significant unmet medical needs and potentially offering new treatment options for millions of allergy sufferers.
- Market Positioning and Development: Headquartered in Châtillon, France, with North American operations in Warren, NJ, DBV's ordinary shares are traded on Euronext Paris while its ADSs are listed on the Nasdaq Capital Market, reflecting its strategic positioning in the global market.
See More
Total Voting Rights and Shares as of February 28, 2026
- Total Shares: As of February 28, 2026, the company has a total of 278,352,082 shares, reflecting the company's stability in the market and transparency in shareholder structure, which ensures investor confidence in corporate governance.
- Total Voting Rights: The total voting rights on the same date amount to 278,352,082, indicating the distribution of voting rights at shareholder meetings, which facilitates shareholder participation in corporate decision-making processes.
- Net Voting Rights: The net voting rights stand at 278,236,200, suggesting that a certain proportion of shares lack voting rights, which may impact shareholders' influence and voice in significant decisions.
- Compliance Information: The disclosure of voting rights and share information is in accordance with Article 223-16 of the French Financial Markets Authority, enhancing market transparency and compliance, thus meeting regulatory requirements.
See More
DBV Technologies Presents Positive Data from VIASKIN® Peanut Patch Study
- Clinical Trial Success: At the AAAAI 2026 Annual Meeting, DBV Technologies presented data from the Phase 3 VITESSE study of the VIASKIN® Peanut Patch, showing that 83% of children increased their eliciting dose at 12 months compared to 48% in the placebo group, indicating significant efficacy of this treatment in peanut-allergic children.
- Significant Treatment Effect: Among the treated group, 46.6% of children met the treatment responder criteria at 12 months, compared to only 14.8% in the placebo group, with a difference of 31.8%, exceeding the pre-specified threshold of 15%, thus laying a solid foundation for future FDA applications.
- Good Safety Profile: The VIASKIN® Peanut Patch was well tolerated, with the majority of treatment-emergent adverse events being mild local reactions, consistent with DBV's previous Phase 3 studies, demonstrating the product's safety in clinical applications.
- Huge Market Potential: If approved, the VIASKIN® Peanut Patch would provide a non-invasive treatment option for peanut-allergic children that fits into daily activities, with DBV planning to submit a Biologics License Application to the FDA in the first half of this year, further advancing its market entry.
See More
DBV Technologies to Present VIASKIN® Data at AAAAI 2026
- Research Data Presentation: DBV Technologies will present additional data from the VITESSE Phase 3 study of the VIASKIN® Peanut Patch for children aged 4-7 at the 2026 AAAAI Annual Meeting, which is expected to enhance market awareness and trust in the product.
- Expert Panel Discussion: During the conference, a panel discussion on the potential of epicutaneous immunotherapy (EPIT) will explore the impact of early intervention in children with peanut allergies, potentially driving the adoption of new treatment options.
- Oral Abstract Presentation: DBV will deliver an oral abstract presentation on February 28, detailing the efficacy and safety of EPIT in peanut-allergic children, further validating its clinical application effectiveness.
- Exhibition Participation: DBV will exhibit at booth #1527 at the AAAAI conference, attracting attendees to learn about the latest developments in EPIT, which may facilitate the company's market share growth in food allergy treatment.
See More
DBV Technologies to Participate in Biotech Summit
- Executive Participation: DBV Technologies CEO Daniel Tassé will participate in a fireside chat at the Guggenheim Securities Biotech Summit on February 12, 2026, at 2:30 PM in New York, showcasing the company's advancements in biopharmaceuticals and likely attracting investor interest.
- Technological Innovation: DBV is focused on developing its proprietary VIASKIN® patch technology to address food allergies and other immunologic conditions, aiming to introduce microgram amounts of biologically active compounds through the skin to retrain the immune system, providing new treatment options for millions of allergy sufferers.
- Clinical Trial Progress: The company is currently conducting clinical trials of the VIASKIN® Peanut patch for peanut-allergic toddlers and children aged 1 to 7 years, demonstrating its commitment and potential to meet significant unmet medical needs in the allergy treatment space.
- Market Positioning and Growth: Headquartered in Châtillon, France, with North American operations in Warren, NJ, DBV's ordinary shares are traded on Euronext Paris while its ADSs are listed on Nasdaq, reflecting its strategic positioning in the global market.
See More
